According to the Declaration of the European Parliament of June 14, 2012, on establishing a European Cardiac Arrest (CA) Awareness Week, it is estimated that some 400,000 people in Europe experience a sudden out-of-hospital CA each year, with a survival rate around 10% (1) . Survival rate after successful cardiopulmonary resuscitation largely depends on residual function of the heart and the degree of permanent brain damage. CA is therefore a devastating disease in terms of both morbidity and mortality.
The ability to accurately predict outcome within 48 h of admission to the intensive care unit (ICU) in patients resuscitated from CA would be a major achievement. Health care providers consider that this prediction would allow a personalized therapy that would benefit the patient. Maximal cardiac supportive treatment could be applied to patients with a possible good neurological outcome. On the other hand, treatment could be alleviated in those with a futile neurological prognosis. However, accurate methods for early outcome prediction after CA are still lacking.
Initial reports of the out-of-hospital CA score (2) , which used several variables readily available at admission to the ICU, have not been replicated (3) . Neurophysiological tests such as electroencephalography (EEG) (4) (5) (6) or somatosensory evoked potentials (7, 8) have been suggested to predict outcome after CA. However, while useful in some situations, these methods are not universally applicable in clinical practice because they require specially trained consultants. Bispectral index (BIS) monitoring, an electroencephalographic monitoring method initially designed to measure the depth of anesthesia, has some potential in predicting brain damage after therapeutic hypothermia in CA patients (9) (10) (11) . Recently, Riker et al. (12) suggested that BIS monitoring may aid in the identification of patients susceptible to waking up during therapeutic hypothermia. The main advantages of BIS monitoring are its ease of use and therefore its potential for widespread use.
Circulating levels of the biomarkers neuron-specific enolase (NSE) and neuron-enriched S100 beta (S100b) may aid in the prognostication of outcomes after CA (13) (14) (15) . The use of NSE in this context is recommended in the guidelines of the American Academy of Neurology to predict outcomes in survivors of CA (16) . These guidelines stated that, due to insufficient data, the use of other markers cannot be either supported or rejected. Furthermore, most data were based on non-hypothermia-treated patients. The 2010 European Resuscitation Council guidelines also stipulated that, due to a lack of evidence, biomarkers should not be used as the sole predictors of outcome (17) . For the same reason, these guidelines also advocate greatest care when using electrophysiological tests for prognostication.
We hypothesized that combined biomarker determination and BIS monitoring may improve outcomes prediction in patients resuscitated from CA.
Methods
Patients. From April 2008 to July 2011, 87 patients with CA were admitted to the 18-bed adult general ICU of an academic tertiary care hospital in Luxembourg. Of these, 75 patients were enrolled in this prospective observational study. The remaining 12 patients had either no blood sample from which to measure biomarkers or were enrolled in another ongoing study. All patients were unconscious on admission, with a Glasgow coma score below 8. The biomarker research protocol was approved by the national research ethics board (National Committee for Ethics in Research of Luxembourg). Informed consent was obtained from all survivors or their legal representatives. Patients were treated with hypothermia at 33 C for 24 h after successful resuscitation. All patients were sedated according to a standard sedation protocol using midazolam (maximum dosage: 0.2 mg/kg/h) and fentanyl (maximum dosage: 1.5 mg/kg/h).
A continuous infusion of cisatracurium (0.1 mg/kg/h) was used to avoid shivering and muscular artefacts on BIS monitoring. No patient woke up during the first 48 h, as all patients were sedated for at least 36 h (24 h of hypothermia and 12 h of rewarming phase) with long-acting sedatives (midazolam). Blood samples for biomarker determination were drawn in citrated tubes 48 h after CA, when patients had returned to normothermia.
In patients who did not regain consciousness, no withdrawal or withholding of any treatment was done before at least 5 days after complete stop of sedation, unless clinical signs of brain death were evident.
Neurological evaluation was performed before discharge from the ICU and after 6 months. Patients were classified according to cerebral performance category (CPC) score, as follows: 1 or 2 ¼ no or minor neurological sequelae; 3 or 4 ¼ severe neurological sequelae or coma; and 5 ¼ death. Measurement of serum markers. Serum level of NSE was assessed on the Cobas e601 analyzer by the electrochemiluminescence immunoassay method (Roche Diagnostics, Mannheim, Germany). The lower limit of quantification of the assay was 0.05 mg/l. Serum level of S100b was assessed by enzyme-linked immunosorbent assay (BioVendor, Heidelberg, Germany). The lower limit of quantification of the assay was 0.015 mg/l. S100b was measured a posteriori, with physicians obviously blinded to the results. Bispectral index monitoring. Since 2005, all CA patients in our institution have undergone routine BIS XP monitoring with a Quatro sensor (ASPECT Medical Systems Inc., Newton, Massachusetts), integrated to standard ICU monitoring (IntelliVue, Philips, Böblingen, Germany) after admission to the ICU. BIS is an EEG monitoring method using a Fourier transformation to convert raw EEG signals into a number from 0 (flat EEG) to 100 (normal electric activity of an awake patient). In our study, only BIS values with a signal quality index above 80% and an electromyography noise signal below 40 dB were used for analyses. As all patients were paralyzed during the recording phase, muscle artefacts (high electromyography noise) could be excluded. BIS values were continuously recorded during the first 48 h after ICU admission. The lowest BIS value within this period was used for analysis. Statistical analysis. All analyses were preceded by the Shapiro-Wilk normality test. Comparisons of normally distributed data between 2 groups were performed by t test. The nonparametric Mann-Whitney U test on ranks was used for non-normally distributed data. Categorical data were analyzed with the chi-square test and the Fisher exact test. Correlation between two variables was assessed with the Spearman test on ranks. A p value <0.05 was considered significant. Analyses were performed with SigmaPlot version 11.0 (Systat Software, Inc., Chicago, Illinois).
Prediction analyses were performed with the Predict-ABLE package on the R 2.14.2 statistical platform. A p value <0.05 was considered statistically significant. Multiple logistic regression models were used for the prediction of neurological outcomes, as assessed by a binary transformation of CPC (CPC 1 or 2 ¼ 0; and CPC 3-5 ¼ 1). Multivariable analysis using multiple logistic regression proceeding by stepwise backward elimination was used to evaluate the predictive value of selected predictors with respect to clinical indicators of prognosis. The area under the receiver-operating characteristic curve (AUC) and the risk ratios were computed to estimate predictive values. The value of adding a variable to a model was evaluated by analysis of deviance and was tested for significance using the Wald chi-square test. Reclassification analyses and integrated discrimination improvement (IDI) were used to evaluate the capacity of new markers to improve the discrimination of patients misclassified by initial markers (18) . Statistical significance was evaluated as described (19) .
Survival analyses were performed using Kaplan-Meier curves and the log-rank statistic.
Results
Patients. Seventy-five CA patients treated with therapeutic hypothermia were enrolled in this study. Clinical characteristics are shown in Table 1 . At 6-month follow-up, 41 patients (55%) had a good neurological outcome (CPC 1 or 2), and 34 patients had a poor outcome (CPC 3-5). Of the latter, 29 patients died during follow-up. The sex ratio was similar between patients with good and poor outcomes. Patients with poor outcomes were older. Clinical parameters potentially reflecting disease severity (simplified acute Serum biomarker levels and BIS monitoring. Forty-eight hours after CA, serum levels of NSE and S100b were significantly higher in patients with poor outcomes compared with those in patients with good outcomes (4fold and 10-fold, respectively; p < 0.001) (Figs. 1A and 1B). Of note, serum levels of NSE and S100b were highly correlated (r: 0.61; p ¼ 4 Â 10 -11 ). BIS was higher in patients with good outcomes compared with that in patients with poor outcomes (10-fold; p < 0.001) (Fig. 1C ). The median time until the lowest BIS value was 5 h (range: 4 to 14.5 h) after CA. Prediction of neurological outcome by serum markers and BIS monitoring. Logistic regression was used to determine the ability of serum markers NSE and S100b measured 48 h after CA, and of the lowest value of BIS to predict neurological outcomes at 6 months, as dichotomized by CPC 1 or 2 and CPC 3 to 5. S100b, NSE, and BIS had significant predictive values, with AUCs above 0.80 ( Fig. 2A ). Combined determination of S100b and BIS had an incremental predictive value, with an AUC of 0.95. Combination of S100b and NSE, or BIS and NSE, had lower predictive values (Fig. 2B) . Adding NSE to S100b and BIS did not further improve the prediction (Fig. 2B) . Analysis of deviance confirmed that the addition of S100b to the model with BIS improved the prediction (deviance: 16.3; p ¼ 5 Â 10 -5 ). However, the addition of NSE to the model with S100b and BIS did not improve prediction (deviance: 2.7; p ¼ 0.10). Reclassification analyses were then performed to address the additive value of biomarkers and BIS (Table 2) . First, we assessed the additive value of S100b to BIS monitoring. S100b improved the discrimination based on BIS monitoring (IDI ¼ 0.13; p ¼ 0.0008). On the other hand, BIS improved the discrimination based on S100b, with an IDI of 0.32 (p < 10 -5 ). NSE failed to improve the discrimination of patients misclassified by a model including BIS and S100b. BIS improved the classification of NSE (IDI ¼ 0.14; p ¼ 0.0005). A model with BIS with S100b also improved the classification of NSE (IDI ¼ 0.20; p < 10 -5 ).
Therefore, together, serum level of S100b and BIS monitoring are robust predictors of neurological outcomes after CA. Cutoffs for the prediction of neurological outcomes by S100b and BIS monitoring. We first determined the cutoffs for S100b and BIS monitoring, which provide the best compromise between sensitivity and specificity for the prediction of neurological outcomes (Figs. 3A and 3B ). The cutoff for S100b was 0.03 mg/l, providing a sensitivity of 76%, a specificity of 78%, and a false positive rate of 22%. The cutoff for BIS was 5.5, providing a sensitivity of 85%, a specificity of 83%, and a false positive rate of 17%. Risk ratios of poor neurological outcome were calculated ( Fig. 3C ). Patients with a S100b serum level above 0.03 mg/l (n ¼ 33) had a 3.4-fold higher risk of poor neurological outcomes (95% confidence interval [CI]: 1.88 to 6.34; p < 0.0001). Patients with BIS monitoring below 5.5 (n ¼ 36) had a 6.1-fold higher risk of poor neurological outcomes (95% CI: 2.66 to 10.07; p < 0.0001). Patients with both serum level of S100b above 0.03 mg/l and BIS monitoring below 5.5 (n ¼ 21) had a 3.6-fold higher risk of poor neurological outcome (95% CI: 2.28 to 5.71; p < 0.0001). Second, we determined the cutoff values for optimal prediction of poor outcome. A level of S100b above 0.3 mg/l predicted a poor outcome with a specificity of 100%. A BIS value of 0 predicted a poor outcome with a specificity of 90% and a false positive rate of 10%. As shown in Figure 3D , patients with a S100b level above 0.3 mg/l (n ¼ 7) had a 2.5fold higher risk of poor neurological outcome (95% CI: 1.85 to 3.32; p ¼ 0.003). Patients with a BIS value of 0 (n ¼ 31) had a 5.3-fold higher risk of poor neurological outcome (95% CI: 2.68 to 10.68; p < 0.0001). Patients with S100b level above 0.3 mg/l and a BIS value of 0 (n ¼ 6) had a 2.4-fold higher risk of poor neurological outcomes (95% CI: 1.83 to 3.23; p ¼ 0.007). Prediction of mortality by S100b and BIS monitoring. Average survival time for patients who died during follow-up (n ¼ 29) was 18 days (range: 3 to 107 days). Survival curves are shown in Figure 4 . Patients with a serum level of S100b above the cutoff value of 0.03 mg/l were at a high risk of death during follow-up (log-rank statistic: 17.17; p < 0.001). Patients with a BIS value below the cutoff value of 5.5 were at high risk of death during follow-up (log-rank statistic: 35.79; p < 0.001). Patients with a serum level of S100b above the cutoff value of 0.03 mg/l and a BIS value below the cutoff value of 5.5 were at a high risk of death during follow-up (log-rank statistic: 50.41; p < 0.001). Therefore, serum level of S100b and BIS monitoring are strong predictors of mortality after CA. Added value of S100b and BIS to traditional prognostic indicators. Finally, we evaluated the predictive value of S100b and BIS with respect to other clinical indicators of prognosis: age; sex; SAPS II; time to ROSC; presenting rhythm (asystole/pulseless electric activity vs. ventricular fibrillation/ventricular tachycardia); and associated factors such as cardiogenic shock, acute myocardial infarction, EEG epileptic state, and seizures. Multivariable analyses showed that SAPS II (p ¼ 0.04), presenting rhythm (p ¼ 0.01), S100b (p ¼ 0.01), and BIS (p ¼ 0.01) were independent predictors of neurological outcome. Reclassification analyses attested that S100b and BIS were able to improve the discrimination based on SAPS II and presenting rhythm with an IDI of 0.22 (p ¼ 10 -5 ). Therefore, combined determination of S100b and BIS improves the prediction of outcome by SAPS II and presenting rhythm.
Discussion
We identified a method to accurately predict neurological outcome and survival after CA. This method relies on the measurement of serum levels of S100b and BIS monitoring. While these two markers have previously been considered as potential predictors of outcome after CA, this study is the first to report that combined determination of both markers has an incremental, and very robust, prognostic value.
The patients enrolled in this study were all resuscitated from CA and treated by therapeutic hypothermia. Due to the dichotomization of patients into good-and poor-outcomes groups, certain disease-related parameters obviously differed between groups. But, as discussed previously, those criteria alone are not sufficient to prognosticate outcome (2, 20) . Thus, the impact of our results should not be affected by the significant differences between the 2 groups of patients.
Booth et al. (20) identified from a review of the existing literature 4 clinical indicators that predict death or poor neurological outcome of comatose survivors of CA: absent corneal reflexes, pupillary response, withdrawal response to pain, and motor response at 24 h. These findings suggested that routine clinical examination could predict outcome. However, the studies included in this meta-analysis were performed before 2003, a time when therapeutic hypothermia was not generally performed. In addition, the authors pointed out that clinical examination alone was insufficient to predict prognosis and should be coupled with other tests or biological markers.
The calcium-binding protein S100b is enriched in astroglial cells and can cross the blood-brain barrier after hypoxic damage of the central nervous system. Its routine measurement is simple and relatively inexpensive. S100b is filtrated by the kidney (21) and has an estimated half-life of 2 h (22) . Its serum level increases after CA, and its prognostic value has been studied (23) (24) (25) (26) (27) (28) . Because of mitigated results, its routine use has been, up to now, not recommended (16) .
EEG findings during hypothermia correlate with neuronal injury post-brain anoxia (29) . Amplitude-integrated EEG certainly has some potential for outcome prediction, but this technique, as well as classic EEG, generally require expertise and special training or consultant support (6) . On the other hand, BIS monitoring, which is easily done, appears to be useful to predict outcome after CA (9) (10) (11) 30) . Interestingly, in our study, the lowest values of BIS used for outcome prediction occurred after 5 h (median value), indicating that BIS has the potential for very early prognostication.
NSE has a role in glucose metabolism. As for S100b, NSE is released from the hypoxic brain into the bloodstream, and its serum level correlates with the extent of brain injury. Also, NSE correlates with other markers of brain injury (31) . NSE has a high specificity to predict adverse outcomes when measured in the few days post CA (26, 32) .
A cutoff point of 33 mg/l is recommended (16) . In our study, the specificity obtained with this cutoff was 83%. NSE levels before 24 h post CA should not be used for prognostication, Prediction of Outcome After Cardiac Arrest August 27, 2013:851-8 and this is consistent with our protocol, in which NSE was measured 48 h post CA. From our results, the predictive value of NSE and its potential contribution to a multimarker strategy remain uncertain. Indeed, analysis of ROC curves showed a maximal AUC for NSE of 0.90, albeit very close to the AUC of BIS (0.89). However, analysis of deviance and reclassification analyses attested that NSE did not increase the predictive value of the model with S100b and BIS. This is probably related to the fact that NSE and S100b are both originating from the brain and do not provide independent information. Consistently, a high correlation was found between serum levels of these two markers. These observations are consistent with those from the study by Einav et al. (26) , in which NSE was not an independent predictor of outcome (26) . Interestingly, in this same study, S100b was an independent predictor of outcome, and this is in line with our findings. The prognostic performance of NSE, alone or combined with other markers, deserves further testing.
While a cutoff value of 33 mg/l is generally accepted for NSE, there is to date no consensus on the cutoff value for S100b. In our study, a cutoff value of 0.03 mg/l of S100b was found to predict neurological outcomes with a sensitivity of 76% and a specificity of 78%. This cutoff value is lower than the cutoff values reported by Einav et al. (26) , which ranged from 0.2 to 100 mg/l, depending on the presenting rhythm of the patients, their age, and the time of blood sampling. It should be noted that not all patients in the study by Einav et al. were treated with therapeutic hypothermia, which may explain the higher cutoff values obtained in that study compared to our study. In the study by Mortberg et al. (33) , a cutoff value of 0.18 mg/l was retained. In the study by Rundgren et al. (13) , levels of S100b above 0.51 mg/l at 24 h predicted poor outcome with a specificity of 96%. In those three studies, the cutoff values were chosen for the prediction of poor outcome, while our cutoff value of 0.03 mg/l was chosen to provide the most accurate prediction of both poor and good outcomes. In a second phase, we observed that a cutoff value of 0.3 mg/l predicted poor outcome with a specificity of 100%, meaning that all patients with a S100b level above 0.3 mg/l had a poor outcome. This cutoff, which is in line with those from previous studies (13, 26, 33) , suggests that a single determination of S100b would be sufficient to establish a secure prognostic. However, this speculation is limited by the few patients presenting with such a high level of S100b. Overall, the cutoff values of S100b remain to be determined in larger populations, taking into account the demographic and clinical characteristics of each individual patient.
Although an accurate and reliable method to prognosticate patients with CA is still needed, several indicators of prognosis are available to the treating physician. In our group of patients, SAPS II and presenting rhythm were significant predictors of neurological outcome. Interestingly, we observed that combined determination of S100b and BIS had an incremental predictive value. Study limitations. First, we must acknowledge that BIS is a processed EEG signal that monitors only a limited area of the brain and not the whole cortex, as standard EEG does. In order to eliminate electromyography artefacts, the patients have to be under neuromuscular blockade, at least during the first hours of BIS measurements. Furthermore, although a continuous EEG tracing is shown on the monitoring, it is not suitable for detection of any particular EEG patterns, such as burst suppression or epileptic state. Standard EEG is still required for the diagnosis and subsequent treatment of these disorders. Second, the treating physicians were not blinded to our BIS data or NSE values. However, as pointed out by our study protocol, withdrawal or withholding of treatment was done only 5 days after the cessation of sedation. Complete blinding to BIS data is complex because accurate measurements require frequent signal-quality checks to correct electrode application, for instance. Blinding of the treating physician would require a third person to check the accuracy of the BIS monitoring nearly continuously. Furthermore, the BIS data must be masked on the monitoring system and in the patient data chart, which is automatically linked to the monitoring system. This was not feasible in the current study. In contrast, treating physicians were blinded to S100b because it was a completely a posteriori analysis. Third, CPC determination can be subjective (34) . However, this does not represent a major limitation of our study because 85% of patients with a poor CPC had died by the 6-month follow-up. Fourth, the distributions of S100b and BIS were left censored at 0 because 41% of patients had no EEG activity (BIS ¼ 0) and 24% had a S100b level below the detection limit of the assay. However, this censoring does not diminish the predictive value of these markers because it does not affect c statistic. Fifth, the small size of the study population did not allow accurate determination of the prognostic value of each of the nine clinical predictors included in the multivariable analyses.
Conclusions
Using a biochemical and an electrophysiological marker of brain damage, outcomes after CA may be predicted. Further studies are required to confirm our findings.
